Impact of a Plasmodium falciparum AMA1 Vaccine on Antibody Responses in Adult Malians

Alassane Dicko, David J. Diemert, Issaka Sagara et al. · 2007

Read Impact of a Plasmodium falciparum AMA1 Vaccine on Antibody Responses in Adult Malians by Alassane Dicko, David J. Diemert, Issaka Sagara et al. (2007) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0001045.txt.

Description

Alassane Dicko, David Diemert, Issaka Sagara and colleagues measured antibody responses to a malaria vaccine in Malian adults, in PLOS ONE in 2007. The vaccine targeted AMA1, a protein on the malaria parasite's invading form. AMA1 is a leading blood stage vaccine candidate, and in monkeys protection tracked with antibody levels.

Adults in Mali, where malaria is common, joined a randomized, double blind phase one trial. Testing there matters because prior exposure shapes responses in ways clean lab populations cannot show. The team report the vaccine's impact on antibody responses. Early safety and response data decide whether a candidate moves toward trials in children.

Catalog record

CREATORAlassane Dicko, David J. Diemert, Issaka Sagara et al.
YEAR2007
COLLECTIONPAPERS
FORMATTXT
FILE SIZE40 KB
LICENSECreative Commons CC0 License
RIGHTSCC0
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0001045

Browse the full library · About the Tower of Babel